Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

No biotech and no M&A experience. They are clearly pulling in their horns with regard to buying another platform. This was made pretty evident by the use of the cash hoard to finance the second round of stock buy-backs just announced, and now confirmed by this new hire, IMHO.

I'm ok with that, as long as new deals keep coming and at a faster pace. I was worried that Helen would go off and overpay for some new venture, but that seems off the table right now. Stick to your knitting. This company hit $55 when the narrative was simple, i.e. that HALO was a cash generator.

Straightening out the IP worries and and removing the fear of HALO buying a new unknown technology should get us back on track.